Discover the important elements of TREANDA®
TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia
(CLL). Efficacy relative to first-line therapies other than chlorambucil has not
TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s
lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab
or a rituximab-containing regimen.
Important Safety Information
- Serious adverse reactions, including myelosuppression, infections, infusion reactions
and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies,
and extravasation, have been associated with TREANDA. Some reactions, such as myelosuppression,
infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol
and other medications known to cause SJS/TEN), have been fatal. Patients should
be monitored closely for these reactions and treated promptly if any occur
- Adverse reactions may require interventions such as decreasing the dose of TREANDA,
or withholding or delaying treatment
- TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine
or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA
- The most common non-hematologic adverse reactions for CLL (frequency ≥15%) are pyrexia,
nausea and vomiting. The most common non-hematologic adverse reactions for NHL (frequency
≥15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia,
cough, headache, weight decreased, dyspnea, rash, and stomatitis. The most common
hematologic abnormalities for both indications (frequency ≥15%) are lymphopenia,
anemia, leukopenia, thrombocytopenia, and neutropenia
You are encouraged to report side effects of prescription drugs to the FDA. Visit
call 1-800-FDA-1088, or fax to 1-800-FDA-0178.
For more information about TREANDA, ask your doctor or call 1-800-896-5855.
This information does not take the place of talking with your doctor for medical
advice about your condition or treatment.
Please see full Prescribing Information.